wo[Table_Title] Research Report 8 May 2025 电子 Technology Alphabet (GOOGL US): AI 搜索 vs 传统搜索，谷歌靠 AI Overviews 稳短期， 长期拓展搜索新模式 Google Uses AI Overviews to Stabilize, Must Accelerate "Gemini + Search" [Table_yemei1] 热点速评 Flash Analysis 姚书桥 Barney Yao 吴叡霖 Louis Ng barney.sq.yao@htisec.com louis.yl.ng@htisec.com [Table_summary] (Please see APPENDIX 1 for English summary) 事件： 2025 年 5 月 7 日，苹果公司服务高级副总裁 Eddy Cue 在美国司法部对谷歌的反垄断诉讼中作证时表示，苹果正在探 索将 AI 驱动的搜索引擎（如 Perplexity、Anthropic 和 OpenAI 的 ChatGPT）集成到 Safari 浏览器中，作为对谷 ...

Investment Rating - The report maintains the operational expenditure guidance for fiscal year 2025 at $100 million to $120 million and capital expenditure guidance at $15 million to $25 million [2]. Core Insights - The market is expected to view Ballard's Q1 2025 performance positively, as the net loss was below consensus expectations, primarily due to strong revenue performance in the bus segment and effective cost control [1][2]. - The company reported Q1 2025 revenue of $15.4 million, which was below the consensus estimate of $17 million, driven mainly by the bus market, contributing approximately 80% of total revenue [2][3]. - Despite a negative gross margin in Q1 2025, the performance was better than consensus expectations due to lower revenue and manufacturing cost allocation [2]. - The backlog of orders for Q1 2025 was reported at $15.8 million, compared to $18.05 million in Q1 2024, with approximately $9.24 million of this amount expected to be fulfilled within the next 12 months [2]. Summary by Sections Financial Performance - Q1 2025 net revenue was $15 million, a decrease of 37% from Q4 2024 and a 6% increase year-over-year [3]. - Operating costs for Q1 2025 were $19 million, down 31% from Q4 2024 and down 5% year-over-year [3]. - The gross profit for Q1 2025 was -$4 million, with a gross margin of -23%, which is an improvement from -37% in Q1 2024 [3]. - Adjusted net income for Q1 2025 was -$21 million, reflecting a 3% increase from Q4 2024 and a 49% decrease year-over-year [3].

[Table_Title] 研究报告 Research Report 8 May 2025 台湾所乐太阳能（SEDG US） 营收超出预期；2025 年第二季度指引高于一致预期 Scott Darling Catherine Li scott.darling@htisec.com catherine.dy.li@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] 要闻回顾以及最新动态 我们预计市场将把所乐太阳能科技 2025 年第一季度业绩视作利好。公司录得经调净亏损 6600 万美元（一致预期为 亏损 7500 万美元），这主要得益于超预期的营收表现和稳健的成本管控。公司 2025 年第二季度的营收指引高于一 致预期。 点评 2025 年第二季度指引超预期：公司预计 2025 年第二季度营收将达到 2.65 亿-2.85 亿美元（一致预期为 2.46 亿美 元），非通用会计准则下的毛利率为 8%-12%（包含 2%的关税影响），非通用会计准则下的支出费用为 9000-9500 万 美元。 营收超出预期；成本控制稳健：所乐太阳能科技 20 ...

[Table_Title] 研究报告 Research Report 8 May 2025 米高集团 Migao Group (9879 HK) 中国钾肥领先企业，积极拓展海外市场 The leading potash fertilizer enterprise in China, actively expanding overseas markets 孙小涵 Xiaohan Sun xh.sun@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) [Table_yejiao1] 本研究报告由海通国际分销，海通国际是由海通国际研究有限公司，海通证券印度私人有限公司，海通国际株式会社和海通国 际证券集团其他各成员单位的证券研究团队所组成的全球品牌，海通国际证券集团各成员分别在其许可的司法管辖区内从事证 券活动。关于海通国际的分析师证明，重要披露声明和免责声明，请参阅附录。(Please see appendix for English translati ...

Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies within the industrial and energy sectors. Core Insights - The "Industrial + Energy" segment of Berkshire Hathaway has evolved into a pillar business alongside insurance and consumer operations, with assets now exceeding $230 billion, contributing approximately 30% of the Group's operating profit [6][14] - Greg Abel's appointment as CEO signifies the continuation of Berkshire's capital allocation philosophy focused on operations, cash flow, and low speculation, particularly in high-barrier, capital-intensive sectors [2][12][13] Summary by Sections Utilities Sector - Berkshire Hathaway Energy (BHE) has over $140 billion in assets and generates annual revenues exceeding $25 billion, benefiting from regulated electricity and gas infrastructure, which provides stable cash flows [6][14][15] - The utility sector is characterized by high entry barriers, requiring significant capital investment and long approval cycles, making it difficult for new entrants to compete [7][15] Industrial Sector - Precision Castparts Corp. (PCC) is a key investment in the industrial sector, specializing in high-performance components for aerospace and defense, with a complex manufacturing process that creates substantial technical barriers [8][16] - The industrial sector's competitive landscape is stable due to high customer switching costs and long qualification cycles for new entrants, reinforcing Berkshire's preference for capital-intensive and high-barrier investments [8][16] Investment Recommendations - The report suggests focusing on companies with unique competitive advantages in the industrial and energy sectors, particularly those with regulated assets and stable cash flows, such as Williams Companies, Kinder Morgan, and Entergy [9][18] - In the industrial space, attention is recommended for firms with strong positions in aerospace and defense components, including Howmet Aerospace and Rolls-Royce, aligning with Berkshire's investment criteria [9][18]

研究报告 Research Report 8 May 2025 中国必需消费 China (A-share) Staples 中国消费行业 2025 年 5 月投资策略：热点增多弱化消费板块行情 The Increase in Hotspots Has Weakened Consumer Stocks [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | --- | --- | --- | | 股票名称 | 评级 股票名称 | 评级 | | 贵州茅台 | Outperform 古井贡酒 | Neutral | | 五粮液 | Outperform 今世缘 | Outperform | | 山西汾酒 | Outperform 燕京啤酒 | Outperform | | 海天味业 | Outperform 迎驾贡酒 | Outperform | | 伊利股份 | Outperform 安琪酵母 | Outperform | | 泸州老窖 | Outperform 重庆啤酒 | Outperform | | 东鹏饮料 | Outperform 盐津铺 ...

[Table_Title] 研究报告 Research Report 8 May 2025 [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) [Table_yejiao1] 本研究报告由海通国际分销，海通国际是由海通国际研究有限公司，海通证券印度私人有限公司，海通国际株式会社和海通国 际证券集团其他各成员单位的证券研究团队所组成的全球品牌，海通国际证券集团各成员分别在其许可的司法管辖区内从事证 券活动。关于海通国际的分析师证明，重要披露声明和免责声明，请参阅附录。(Please see appendix for English translation of the disclaimer) 25Q1 净利润实现扭亏为盈。第一季度销售额为 10 亿美元，以美元计算同比减少约 5%，以人民币计算同比减 少 4%，以固定汇率计算同比减少 3%，主要反映了销量持平，价格下降 4%以及汇率波动不利的影响。大部分 区域渠道存货水平进一步改善，公司销量总体保持稳定，主要受土耳其业务减少（ ...

Investment Rating - The report maintains an "Outperform" rating for BeiGene with a target price of HK$182.35, while the current price is HK$141.00 [2][6]. Core Insights - In Q1 2025, BeiGene achieved revenue of USD1.12 billion, a year-on-year increase of 48.6%, with product revenue at USD1.11 billion. The net income attributable to shareholders was USD1.27 million, marking the first quarterly recurring business profit under US GAAP [3][13]. - The growth in overseas revenue, particularly from BRUKINSA, was a significant driver for the company's turnaround to profitability [4][14]. - The management has maintained its full-year revenue guidance of USD4.9 billion to USD5.3 billion, indicating confidence in future performance [3][13]. Financial Performance Summary - Revenue projections for the upcoming years are as follows: USD5.01 billion in FY2025, and USD6.03 billion in FY2026, reflecting growth rates of 31% and 20% respectively [11]. - The net profit is expected to turn positive in FY2025 with a forecast of USD34 million, and further increase to USD390 million in FY2026, showing a significant recovery from previous losses [11]. - Gross profit margin (GPM) is projected to improve slightly from 84.7% in FY2025 to 85.0% in FY2026 [11]. Product Performance - BRUKINSA generated revenue of USD790 million in Q1 2025, a year-on-year increase of 62.1%. The U.S. sales reached USD563 million, while European sales were USD116 million, indicating strong international demand [4][14]. - The report highlights that BRUKINSA's terminal sales in hospitals increased by 9.2% quarter-on-quarter, suggesting continued growth potential [4][14]. Expense Management - The report notes continuous optimization of expense ratios, with a gross profit margin of 85.2% in Q1 2025, up by 1.9 percentage points year-on-year. R&D expenses were USD482 million, with a reduced R&D expense ratio of 43.1% [5][15]. - Operating profit improved to USD11.1 million in Q1 2025, compared to a loss of USD261 million in the same quarter of the previous year [5][15].

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of RMB 46.69, corresponding to a 2025 PE of 32X [4][8]. Core Insights - The company experienced a revenue of RMB 443 million in 2024, a decrease of 5.90% year-on-year, while the net profit attributable to shareholders was RMB 135 million, down 7.11% [4][8]. - In Q1 2025, the company reported a revenue of RMB 147 million, reflecting a significant increase of 24.86% year-on-year, and a net profit of RMB 47 million, up 21.45% [4][8]. - The company’s EPS forecasts for 2025-2026 are RMB 1.48 and RMB 1.85, with a new forecast for 2027 at RMB 2.28 [4][8]. Financial Summary - The financial summary indicates that in 2023, the company had a revenue of RMB 471 million, which decreased to RMB 443 million in 2024, with projections of RMB 556 million in 2025 and RMB 681 million in 2026 [3][4]. - The net profit attributable to shareholders was RMB 146 million in 2023, decreasing to RMB 135 million in 2024, with an expected increase to RMB 179 million in 2025 and RMB 223 million in 2026 [3][4]. - The gross profit margin for 2024 was 64.51%, showing a slight increase from the previous year, and the first quarter of 2025 reported a gross profit margin of 64.98% [11]. Customer Orders and Market Expansion - Customer orders are recovering, with shipment volumes increasing significantly, particularly in Q1 2025, where shipments grew over 40% year-on-year and quarter-on-quarter [9]. - The company’s ODM business revenue was RMB 281 million in 2024, accounting for 63.81% of total revenue, while the self-owned brand product revenue was RMB 65.22 million, representing 14.80% [10]. Profitability and Cost Management - The overall gross profit margin remained stable, with expectations for long-term profitability to be maintained due to improvements in overseas subsidiaries' capacity and management [11]. - The company has increased its R&D and marketing expenses significantly in 2024 compared to 2023, which is expected to support future growth [11].

Investment Rating - The report initiates coverage with an "Outperform" rating for the company [1][4][13]. Core Views - The company has emerged from the impact of centralized procurement, achieving strong growth on a low base in its traditional orthopedic segment, while successfully expanding into new business areas [1][14]. - The forecasted EPS for 2025-2026 is RMB 1.24 and RMB 1.64, with a new forecast for 2027 at RMB 1.99. A target PE of 36X for 2025 is set, leading to a target price of RMB 44.64 [4][13][14]. Financial Summary - In 2024, the company is expected to achieve revenue of RMB 2.14 billion, a year-on-year increase of 39.3%, and a net profit attributable to shareholders of RMB 357 million, reflecting a 505% increase [3][14]. - For Q1 2025, revenue is projected at RMB 550 million, up 28.8%, with a net profit of RMB 103 million, an increase of 67% [3][14]. - The company’s revenue growth is attributed to the clearing of inventory adjustments from previous centralized procurement impacts, leading to a strong performance in 2024 [14][15]. Product Line Performance - The core orthopedic product lines have recovered post-centralized procurement, with trauma product sales expected to reach RMB 821 million in 2024, a growth of 43.4%, and a gross profit margin increase of 3.67 percentage points to 75.34% [15][16]. - Spine product revenue is anticipated to be RMB 388 million, a 36.9% increase, while joint products are expected to grow by 21.1% to RMB 189 million [15][16]. Non-Orthopedic Growth - The company is expanding its non-orthopedic consumables business, aiming to become a platform company in medical equipment. R&D investment in 2024 is projected at RMB 307 million, representing 14.4% of revenue [16][10]. - Revenue from minimally invasive surgical products is expected to reach RMB 363 million, a growth of 26.5%, with a gross profit margin increase of 1.77 percentage points to 78.19% [16][10].